Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia

S. H. Chen, D. C. Liang, M. Lin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A 9-year-old girl with severe refractory aplastic anemia had become refractory to platelet transfusion due to platelet alloimmunization. As a result, a huge right parieto-temporo-occipital cerebral hematoma and a subarachnoid hemorrhage subsequently occurred. Intravenous immunoglobulin (IVIG) (Green Cross, Taiwan) at a dose of 0.4 g/kg/day for 5 days, followed by another 3 doses during the following 5 days, and combined with large-dose platelet transfusions effectively controlled the bleeding by elevating the platelet count to above 100 x 103/mm3. The patient soon recovered with only a mild sequela. Two months later, because of multiple caries and a periodontal abscess, dental extraction needed to be performed. IVIG (0.4 g/kg/day x 6 days) enabled surgery to proceed by elevating the platelet count to above 55 x 103/mm3, and no bleeding complications occurred during or after the procedure. The potential benefit of high-dose IVIG in modulating platelet alloimmunization is a result of increasing the survival of transfused platelets. Thus, this therapy is recommended when patients with platelet alloimmunization have critical bleeding episodes or undergo surgical procedures.

Original languageEnglish
Pages (from-to)165-166
Number of pages2
JournalAmerican Journal of Hematology
Volume49
Issue number2
DOIs
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Aplastic Anemia
Intravenous Immunoglobulins
Blood Platelets
Platelet Transfusion
Hemorrhage
Platelet Count
Periodontal Abscess
Refractory Anemia
Tooth Extraction
Subarachnoid Hemorrhage
Therapeutics
Ambulatory Surgical Procedures
Taiwan
Hematoma
Survival

Keywords

  • Aplastic anemia
  • Intracranial hemorrhage
  • IVIG
  • Platelet alloimmunization

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia. / Chen, S. H.; Liang, D. C.; Lin, M.

In: American Journal of Hematology, Vol. 49, No. 2, 1995, p. 165-166.

Research output: Contribution to journalArticle

@article{36c90a54221f4750858b8138dc8538b1,
title = "Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia",
abstract = "A 9-year-old girl with severe refractory aplastic anemia had become refractory to platelet transfusion due to platelet alloimmunization. As a result, a huge right parieto-temporo-occipital cerebral hematoma and a subarachnoid hemorrhage subsequently occurred. Intravenous immunoglobulin (IVIG) (Green Cross, Taiwan) at a dose of 0.4 g/kg/day for 5 days, followed by another 3 doses during the following 5 days, and combined with large-dose platelet transfusions effectively controlled the bleeding by elevating the platelet count to above 100 x 103/mm3. The patient soon recovered with only a mild sequela. Two months later, because of multiple caries and a periodontal abscess, dental extraction needed to be performed. IVIG (0.4 g/kg/day x 6 days) enabled surgery to proceed by elevating the platelet count to above 55 x 103/mm3, and no bleeding complications occurred during or after the procedure. The potential benefit of high-dose IVIG in modulating platelet alloimmunization is a result of increasing the survival of transfused platelets. Thus, this therapy is recommended when patients with platelet alloimmunization have critical bleeding episodes or undergo surgical procedures.",
keywords = "Aplastic anemia, Intracranial hemorrhage, IVIG, Platelet alloimmunization",
author = "Chen, {S. H.} and Liang, {D. C.} and M. Lin",
year = "1995",
doi = "10.1002/ajh.2830490213",
language = "English",
volume = "49",
pages = "165--166",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia

AU - Chen, S. H.

AU - Liang, D. C.

AU - Lin, M.

PY - 1995

Y1 - 1995

N2 - A 9-year-old girl with severe refractory aplastic anemia had become refractory to platelet transfusion due to platelet alloimmunization. As a result, a huge right parieto-temporo-occipital cerebral hematoma and a subarachnoid hemorrhage subsequently occurred. Intravenous immunoglobulin (IVIG) (Green Cross, Taiwan) at a dose of 0.4 g/kg/day for 5 days, followed by another 3 doses during the following 5 days, and combined with large-dose platelet transfusions effectively controlled the bleeding by elevating the platelet count to above 100 x 103/mm3. The patient soon recovered with only a mild sequela. Two months later, because of multiple caries and a periodontal abscess, dental extraction needed to be performed. IVIG (0.4 g/kg/day x 6 days) enabled surgery to proceed by elevating the platelet count to above 55 x 103/mm3, and no bleeding complications occurred during or after the procedure. The potential benefit of high-dose IVIG in modulating platelet alloimmunization is a result of increasing the survival of transfused platelets. Thus, this therapy is recommended when patients with platelet alloimmunization have critical bleeding episodes or undergo surgical procedures.

AB - A 9-year-old girl with severe refractory aplastic anemia had become refractory to platelet transfusion due to platelet alloimmunization. As a result, a huge right parieto-temporo-occipital cerebral hematoma and a subarachnoid hemorrhage subsequently occurred. Intravenous immunoglobulin (IVIG) (Green Cross, Taiwan) at a dose of 0.4 g/kg/day for 5 days, followed by another 3 doses during the following 5 days, and combined with large-dose platelet transfusions effectively controlled the bleeding by elevating the platelet count to above 100 x 103/mm3. The patient soon recovered with only a mild sequela. Two months later, because of multiple caries and a periodontal abscess, dental extraction needed to be performed. IVIG (0.4 g/kg/day x 6 days) enabled surgery to proceed by elevating the platelet count to above 55 x 103/mm3, and no bleeding complications occurred during or after the procedure. The potential benefit of high-dose IVIG in modulating platelet alloimmunization is a result of increasing the survival of transfused platelets. Thus, this therapy is recommended when patients with platelet alloimmunization have critical bleeding episodes or undergo surgical procedures.

KW - Aplastic anemia

KW - Intracranial hemorrhage

KW - IVIG

KW - Platelet alloimmunization

UR - http://www.scopus.com/inward/record.url?scp=0029004809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029004809&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830490213

DO - 10.1002/ajh.2830490213

M3 - Article

VL - 49

SP - 165

EP - 166

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -